Adherence : The Goal to Control Asthma - 26/08/12
, Daniel Vervloet, MD b, Yves Magar, MD c, Juliet M. Foster, PhD dRésumé |
Asthma management requires adequate adherence to many recommendations, including therapy, monitoring of asthma control, avoidance of environmental triggers, and attending follow-up appointments. Poor adherence is common in patients with asthma and is often associated with increased health care use, morbidity, and mortality. Many determinants of poor adherence have been identified and should be addressed, but there is no clear profile of the nonadherent patient. Interventions to improve adherence therefore demand tailoring to the individual by including patient-specific education, addressing patient fears and misconceptions, monitoring adherence, and developing a shared decision process.
Le texte complet de cet article est disponible en PDF.Keywords : Adherence, Compliance, Asthma control
Plan
| Disclosure: LPB: Advisory Boards: AstraZeneca, GlaxoSmithKline, Merck, and Novartis. Lecture fees: 3M, AstraZeneca, GlaxoSmithKline, Merck, and Novartis. Sponsorship for investigator-generated research: AstraZeneca, GSK, Merck, and Schering. Research funding for participating in multicenter studies: Altair, Asmacure, AstraZeneca, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Pharmaxis, Schering, Wyeth. Support for the production of educational materials: AstraZeneca, GlaxoSmithKline, and Merck Frosst. Governmental: Adviser for the Quebec INNESS. Organizational: Chair of the Canadian Thoracic Society Respiratory Guideline Committee and chair of GINA Guidelines Dissemination and Implementation Committee. Laval University Chair on Knowledge Translation, Prevention and Education in Respiratory and Cardiovascular Health. Member Knowledge Translation Canada (Canadian Institutes of Health Research). DV: GlaxoSmithKline, AstraZeneca, Stallergenes, ALK, MundiPharma. YM: Lecture or training sessions fees: AstraZeneca, GlaxoSmithKline, MSD. JMF: Research funding: AstraZeneca and Nycomed. Lecture fees: AstraZeneca, Pharmaceutical Society of Australia and GlaxoSmithKline. |
Vol 33 - N° 3
P. 405-417 - septembre 2012 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
